Compare IDAI & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDAI | AIMD |
|---|---|---|
| Founded | 2016 | 1984 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9M | 13.1M |
| IPO Year | 2022 | N/A |
| Metric | IDAI | AIMD |
|---|---|---|
| Price | $2.07 | $1.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 46.3K | 12.9K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $103.06 | N/A |
| Revenue Next Year | $140.06 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $0.44 |
| 52 Week High | $5.28 | $4.50 |
| Indicator | IDAI | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 35.25 | 37.78 |
| Support Level | N/A | $1.33 |
| Resistance Level | $2.76 | $1.69 |
| Average True Range (ATR) | 0.17 | 0.09 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 0.00 | 8.62 |
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.